The mission of the Masonic Cancer Center (MCC) Flow Cytometry Shared Resource (FCSR) is to provide comprehensive state-of-the-art services and training in all aspects of flow cytometry to MCC personnel in a cost-effective manner. The FCSR has facilities in both the Masonic Cancer Research Building (MCRB) and the Cancer and Cardiovascular Research Building (CCRB). Several years ago, the FCSR was one of several independent flow cytometry facilities in the Academic Health Center (AHC) at the University of Minnesota; each was administered by a separate Center, Department, or Institute. The directors of these facilities and AHC leadership decided to merge the flow cytometry facilities under one administrative umbrella with centralized financial support from the AHC. This new University Flow Cytometry Resource (UFCR) provided an economy of scale, more funds to purchase equipment, and uniformity of support among the AHC centers and institutes that require flow cytometry equipment and expertise. It also allowed MCC researchers not housed in MCRB or CCRB to access flow cytometry facilities other than FCSR and still receive an MCC subsidy for equipment use. The FCSR is the largest of the 4 members in the UFCR consortium in terms of usage (approximately 80% of billed hours) and instrumentation (7 of 10 flow cytometers, 2 of 3 cell sorters, and 2 of 2 data analysis work stations). The FCSR Director of Daily Operations is Mr. Paul Champoux; he is supported by 3 full-time personnel, AHC administration, and a 5-member Board of Scientific Directors. Dr. Christopher Pennell serves on this Board as the Scientific Director of Flow Cytometry for MCC. He has oversight for all cancer-related projects that use FCSR, and decisions regarding FCSR or any of the other 3 UFCR members requires Dr. Pennell's agreement; this ensures that FCSR, and UFCR as a whole, meet the flow cytometry needs of MCC researchers. The FCSR regularly partners with industry leaders to test and adopt new flow cytometry technologies, keeping it at the cutting-edge of flow cytometry. As a result, the FCSR has had instrumentation retrofitted with new technologies prior to commercial availability. These advancements have benefitted customers and provided tools for the faculty to remain competitive with their peers, all at very low expense.
The specific aims for the next 5 years are to 1) provide MCC researchers with 24/7 access to advanced flow cytometric instruments; 2) aid MCC researchers in the design of flow cytometry experiments, data acquisition, and data interpretation; 3) educate MCC researchers regarding the principles of flow cytometry and train users on self-service analyzers; 4) beta-test new reagents and equipment and continually upgrade equipment; and 5) share cutting-edge advancements in flow cytometry with MCC researchers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-22
Application #
9859360
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Ustun, C; Brunstein, C; DeFor, T et al. (2018) Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation. Bone Marrow Transplant 53:97-100
How, Joan; Vij, Kiran R; Ebadi, Maryam et al. (2018) Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol 93:E381-E383
Kaizer, Alexander M; Hobbs, Brian P; Koopmeiners, Joseph S (2018) A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies. Biometrics 74:1082-1094
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Li, Danni; Huang, Fangying; Zhao, Yingchun et al. (2018) Plasma lipoproteome in Alzheimer's disease: a proof-of-concept study. Clin Proteomics 15:31
Sperduto, Paul W; Deegan, Brian J; Li, Jing et al. (2018) Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro Oncol 20:1652-1660
Yun, Byeong Hwa; Bellamri, Medjda; Rosenquist, Thomas A et al. (2018) Method for Biomonitoring DNA Adducts in Exfoliated Urinary Cells by Mass Spectrometry. Anal Chem 90:9943-9950
Hwa Yun, Byeong; Guo, Jingshu; Bellamri, Medjda et al. (2018) DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humans. Mass Spectrom Rev :
Owen, David L; Mahmud, Shawn A; Vang, Kieng B et al. (2018) Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. J Immunol 200:3926-3933
Rashidi, Armin; Shanley, Ryan; Yohe, Sophia L et al. (2018) Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. Bone Marrow Transplant 53:1069-1071

Showing the most recent 10 out of 1013 publications